Claims for Patent: 10,039,766

Summary for Patent: 10,039,766

Title:	Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide
Abstract:	The present invention discloses certain new solid state forms of (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide, processes for preparing such forms, pharmaceutical compositions comprising them, and the use of such forms in therapy.
Inventor(s):	Tomkinson Gary Peter
Assignee:	AstraZeneca AB
Application Number:	US15291370
Patent Claims:	2. The method of claim 1 , wherein said Form B is characterized by an X-ray powder diffraction pattern with specific peaks at about 2-theta=10.0 claim 1 , 12.3 claim 1 , 15.0 claim 1 , 17.1 claim 1 , 19.2 and 24.4°.3. The method of claim 1 , wherein said Form B is characterized by an X-ray powder diffraction pattern with at least ten peaks at about 2-theta=15.0 claim 1 , 19.2 claim 1 , 12.3 claim 1 , 10.0 claim 1 , 17.1 claim 1 , 24.4 claim 1 , 16.4 claim 1 , 26.0 claim 1 , 15.5 claim 1 , and 23.9°.4. The method of claim 1 , wherein said Form B is characterized by an X-ray powder diffraction pattern comprising at least ten peaks at about 2-theta=10.0 claim 1 , 5.0 claim 1 , 15.0 claim 1 , 19.2 claim 1 , 17.1 claim 1 , 12.3 claim 1 , 24.4 claim 1 , 30.2 claim 1 , 32.3 claim 1 , and 23.3°.5. The method of claim 1 , wherein administering further comprises administering a pharmaceutical composition comprising (S)-4-Amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2 claim 1 ,3-d]-pyrimidin-4-yl)piperidine-4-carboxamide crystalline Form B and a pharmaceutically-acceptable diluent or carrier.6. The method of claim 1 , wherein administering further comprises administering a pharmaceutical composition comprising (S)-4-Amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2 claim 1 ,3-d]-pyrimidin-4-yl)piperidine-4-carboxamide crystalline Form B microcrystalline cellulose claim 1 , mannitol claim 1 , croscarmellose sodium and magnesium stearate.7. The method of claim 1 , wherein administering further comprises administering a pharmaceutical tablet comprising from 50 to 500 mg of (S)-4-Amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2 claim 1 ,3-d]-pyrimidin-4-yl)piperidine-4-carboxamide crystalline Form B and one or more pharmaceutically acceptable excipients.8. The method of claim 1 , wherein administering further comprises administering a pharmaceutical tablet comprising from 0.5 to 2% by weight of magnesium stearate claim 1 , from 2 to 5% by weight of croscarmellose sodium claim 1 , from 15 to 60% by weight of (S)-4-Amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2 claim 1 ,3-d]-pyrimidin-4-yl)piperidine-4-carboxamide crystalline Form B claim 1 , microcrystalline cellulose and mannitol claim 1 , wherein the relative weights of microcrystalline cellulose and mannitol within the tablet are in a ratio of from 3:1 to 1:1 and wherein the amount of (S)-4-Amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2 claim 1 ,3-d]-pyrimidin-4-yl)piperidine-4-carboxamide crystalline Form B within the tablet is from 50 to 500 mg.